Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diseases of aging
Biotech
BioAge secures Novartis deal worth up to $550M biobucks
The Novartis deal comes less than two weeks after BioAge discarded a phase 2 obesity trial and less than three months after its Nasdaq debut.
Gabrielle Masson
Dec 18, 2024 10:44am
Apollo's mission to extend human health span gets $180M boost
Dec 1, 2021 8:00am
Juvenescence raises $100M to fund longevity R&D
Aug 19, 2019 7:30am
Insights into cell aging could boost search for new cures
Jun 7, 2019 10:05am
Senescence startup Cleara bags cash to move toward the clinic
Jul 6, 2018 11:00am
Unity files for $85M IPO to take anti-aging drugs into phase 1
Apr 6, 2018 8:53am
